Ata F,Yousaf Z,Zahir FZ,Mohamed Babiker A,Ali Farooqi A,Ahmad Al Hiyari M,Mohamed A I,Nashwan AH,Yassin AJ,MA AJ .2022 .. , : .
.2022 .Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population. Qatar Med, : 22.
Beltrami-Moreira M,Bussel JB. .2022 .Low-dose rituximab in immune thrombocytopenia: One and done. , : .
Hematol Am. J. . .. , 97(4) : 388-389.
Bolton-Maggs PHB,George JN .2021 .Immune thrombocytopenia treatment. N. Engl. J. Med, 385(10) : 948-950.
.2020 .(. Zhonghua Xue Ye Xue Za Zhi, 41(8) : 617-623.
Delshad M,Davoodi-Moghaddam Z,PourbagheriSigaroodi A,Faranoush M,Abolghasemi H,Bashash D H .2024 .Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials. Thromb. Res., 235 : 125-147.
DeSouza S and Angelini D.,September -October .2025 .Expanded management options. Cleve. Clin. J. Med, 88(12) : 664-668.
Hamed EM,Ibrahim ARN,Meabed MH,Khalaf AM,El Demerdash DM,Elgendy MO,Saeed H,Salem HF,Rabea H HF .2023 .Therapeutic outcomes of high dosedexamethasone versus prednisolone + azathioprine, rituximab, eltrombopag and romiplostim strategies in persistent, chronic, refractory and relapsed immune thrombocytopenia patients. Pharmaceuticals (Basel), 16(9) : 1215.
Kang H .2021 .Sample size determination and power analysis using the G*Power software. J. Educ. Eval., : .
Prof Health . .. , 18 : 17.
Kaur MN,Arnold DM,Heddle NM,Cook RJ,Hsia C,Blostein M,Jamula E,Sholzberg M,Lin Y,Kassis J,Larratt L,Tinmouth A,Carruthers J,Li N,Liu Y,Xie F Y .2022 .Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Adv., 6(3) : 785-792.
Kochhar M and Neunert C .2021 .Immune thrombocytopenia: A review of upfront treatment strategies. Blood Rev., 49 : 100822.
Li J,Guo J,Yuan R,Xue L R .2025 .Rituximab in Immune-mediated thrombotic thrombocytopenic purpura. Eur J Intern Med., : .
Hou Liu X G,Hou M Y .2023 .How we treat primary immune thrombocytopenia in adults. J. Hematol., : .
. .. , 16(1) : 4.
Nusrat S,Tewari S,Khan O .2023 .Successful treatment of lupus anticoagulant hypoprothrombinemia syndrome with rituximab. Thromb. J., 21(1) : 77.
Oliva EN,Riva M,Niscola P,Santini V,Breccia M,Giai V,Poloni A,Patriarca A,Crisà E,Capodanno I,Salutari P,Reda G,Cascavilla N,Ferrero D,Guarini A,Tripepi G,Iannì G,Russo E,Castelli A,Fattizzo B,Beltrami G,Bocchia M,Molteni A,Fenaux P,Germing U,Ricco A,Palumbo G A,Impera S,Di Renzo N,Rivellini F,Buccisano F,Stamatoullas-Bastard A,Liberati A M,Candoni A,Delfino IM,Arcadi MT,Cufari P,Rizzo L,Bova I,D'Errigo M G G,Latagliata R G .2023 .. , : .
. .Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: Interim results of a phase ii, randomized, placebo-controlled clinical trial (EQOLMDS). J. Clin. Oncol., 41(28) : 4486-4496.
Patel BA,Groarke EM,Lotter J,Shalhoub R,Rios F,Quinones Raffo O,Wu D,Young CO,NS. CO .2022 .Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: A phase 2 study. , 139(1) : 34-43.
Peffault de Latour R,Kulasekararaj A,Iacobelli S,Terwel SR,Cook R,Griffin M,Halkes CJM,Recher C,Barraco F,Forcade E,Vallejo J C,Drexler B,Mear JB,Smith AE,Angelucci E,Raymakers RAP,de Groot MR,Daguindau E,Nur E,Barcellini W,Russell N H,Terriou L,Iori A P,La Rocca U,Sureda A,Sánchez-Ortega I,Xicoy B,Jarque I,Cavenagh J,Sicre de Fontbrune F,Marotta S,Munir T,Tjon JML,Tavitian S,Praire A,Clement L,Rabian F,Marano L,Hill A,Palmisani E,Muus P,Cacace F,Frieri C,Lint MT,Passweg JR,Marsh JCW,Socie G,Mufti GJ,Dufour C,Risitano AM C .2022 .Eltrombopag added to immunosuppression in severe aplastic anemia. N. Engl. J. Med, 386(1) : 11-23.
Sandal R,Mishra K,Jandial A,Sahu KK,Siddiqui AD .2021 .Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev. Clin. Pharmacol, 14(5) : 553-568.
Vianelli N,Auteri G,Buccisano F,Carrai V,Baldacci E,Clissa C,Bartoletti D,Giuffrida G,Magro D,Rivolti E,Esposito D,Podda GM,Palandri F GM .2022 .. , : .
. .. , 101(5) : 963-978.
.2021 .Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N. Engl. J. Med, 384(24) : 2295-2305.
Will B .2022 .Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura. Br. J., : .
. .. , 197(2) : 137-138.
Witkowski M,Ryżewska W,Robak T .2024 .. , : .
. .. , 35(3) : 108-114.
Zhang N,Ji C,Bao X,Yuan C .2022 .Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report. Medicine (Baltimore), 101(2) : e28417.
Zhou H,Fan J,He J,Hu S J .2022 .Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: A multiple-treatments network meta-analysis. , 101(5) : 953-961.